Endothelial TLR4 at the Crossroads of Vascular Senescence and Targeted Senotherapeutics.
Stage: review
· pubmed
· 01-oct-2026
Applies to developers of vascular senotherapeutics: this review argues systemic TLR4 inhibitors are unlikely to work and that endothelium-targeted delivery is the required next step.
Endothelial TLR4 acts as a context-dependent driver of vascular senescence and aging pathologies, so next-generation anti-aging therapy should use spatiotemporally targeted TLR4 inhibition (e.g., VCAM-1/E-selectin nanoparticles or engineered plant exosomes) rather than systemic pan-TLR4 blockade.
Link: /findings/1814